1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia * diagnosed by the attending physician * identified in a chest x-ray 4. fever or cough present for more than 48 hours 5. positive igg against sars-cov-2 by rapid test 6. age under 18 or over 60 years 7. the following co-morbidities (or any other disease that might interfere with the study in the eyes of the investigator): * immunosuppression * chronic obstructive pulmonary disease * diabetes * hypertension * obesity * acute or chronic renal failure * history of coronary disease * history of cerebrovascular disease * current neoplasm 8. recent travel history to countries that are endemic for loa loa (angola, cameroon, central african republic, chad, democratic republic of congo, ethiopia, equatorial, guinea, gabon, republic of congo, nigeria and sudan) 9. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia * diagnosed by the attending physician * identified in a chest x-ray 4. fever or cough present for more than 48 hours 5. positive igg against sars-cov-2 by rapid test 6. age under 18 or over 60 years 7. the following co-morbidities (or any other disease that might interfere with the study in the eyes of the investigator): * immunosuppression * chronic obstructive pulmonary disease * diabetes * hypertension * obesity * acute or chronic renal failure * history of coronary disease * history of cerebrovascular disease * current neoplasm 8. recent travel history to countries that are endemic for loa loa (angola, cameroon, central african republic, chad, democratic republic of congo, ethiopia, equatorial, guinea, gabon, republic of congo, nigeria and sudan) 9. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

known history of ivermectin allergy hypersensitivity to any component of stromectol® covid-19 pneumonia diagnosed by the attending physician identified in a chest x-ray fever or cough present for more than 48 hours positive igg against sars-cov-2 by rapid test age under 18 or over 60 years the following co-morbidities (or any other disease that might interfere with the study in the eyes of the investigator): immunosuppression chronic obstructive pulmonary disease diabetes hypertension obesity acute or chronic renal failure history of coronary disease history of cerebrovascular disease current neoplasm recent travel history to countries that are endemic for loa loa (angola, cameroon, central african republic, chad, democratic republic of congo, ethiopia, equatorial, guinea, gabon, republic of congo, nigeria and sudan) current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

known history of ivermectin allergy hypersensitivity to any component of stromectol® covid-19 pneumonia diagnosed by the attending physician identified in a chest x-ray fever or cough present for more than 48 hours positive igg against sars-cov-2 by rapid test age under 18 or over 60 years the following co-morbidities (or any other disease that might interfere with the study in the eyes of the investigator): immunosuppression chronic obstructive pulmonary disease diabetes hypertension obesity acute or chronic renal failure history of coronary disease history of cerebrovascular disease current neoplasm recent travel history to countries that are endemic for loa loa (angola, cameroon, central african republic, chad, democratic republic of congo, ethiopia, equatorial, guinea, gabon, republic of congo, nigeria and sudan) current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia - diagnosed by the attending physician - identified in a chest x-ray 4. fever or cough present for more than 48 hours 5. positive igg against sars-cov-2 by rapid test 6. age under 18 or over 60 years 7. the following co-morbidities (or any other disease that might interfere with the study in the eyes of the investigator): - immunosuppression - chronic obstructive pulmonary disease - diabetes - hypertension - obesity - acute or chronic renal failure - history of coronary disease - history of cerebrovascular disease - current neoplasm 8. recent travel history to countries that are endemic for loa loa (angola, cameroon, central african republic, chad, democratic republic of congo, ethiopia, equatorial, guinea, gabon, republic of congo, nigeria and sudan) 9. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

1. known history of ivermectin allergy 2. hypersensitivity to any component of stromectol® 3. covid-19 pneumonia - diagnosed by the attending physician - identified in a chest x-ray 4. fever or cough present for more than 48 hours 5. positive igg against sars-cov-2 by rapid test 6. age under 18 or over 60 years 7. the following co-morbidities (or any other disease that might interfere with the study in the eyes of the investigator): - immunosuppression - chronic obstructive pulmonary disease - diabetes - hypertension - obesity - acute or chronic renal failure - history of coronary disease - history of cerebrovascular disease - current neoplasm 8. recent travel history to countries that are endemic for loa loa (angola, cameroon, central african republic, chad, democratic republic of congo, ethiopia, equatorial, guinea, gabon, republic of congo, nigeria and sudan) 9. current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.